Credit Suisse Ag Tango Therapeutics, Inc. Call Options Transaction History
Credit Suisse Ag
- $101 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TNGX
# of Institutions
127Shares Held
88.8MCall Options Held
2KPut Options Held
1.6K-
Trv Gp Iv, LLC Boston, MA19.2MShares$164 Million73.88% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA13.3MShares$114 Million3.02% of portfolio
-
Boxer Capital, LLC San Diego, CA8.2MShares$70.2 Million3.39% of portfolio
-
Nextech Invest Ag5.53MShares$47.4 Million8.22% of portfolio
-
Southpoint Capital Advisors LP New York, NY5.28MShares$45.2 Million0.95% of portfolio
About Tango Therapeutics, Inc.
- Ticker TNGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 88,067,296
- Market Cap $754M
- Description
- Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...